SkinBioTherapeutics PLC (AIM:SBTX)'s chief executive Stuart Ashman sat down with Proactive London to discuss AxisBiotix-Ps, the company's food supplement used to alleviate symptoms associated with psoriasis.
The supplement has begun to generate revenue just five months since its launch, with a 69% retention rate.
A further roll-out across Europe is targeted over the next six months, as well as developing its acne food supplement, with a consumer study targeted for the end of the year.